MedPath

Protocol-Specified Modification of Immunosuppression Directed to Protocol Biopsy in Kidney Transplantation

Not Applicable
Conditions
Surveillance Protocol Biopsy
Interventions
Procedure: Surveillance protocol kidney allograft biopsy
Registration Number
NCT02294097
Lead Sponsor
Chulalongkorn University
Brief Summary

The risk-benefit of surveillance-protocol biopsy (SPBx) in kidney transplantation remains unclear. The study aims to compare outcomes of recipients with SPBx approach to recipients with standard approach which allograft biopsy was performed only when indicated.

Detailed Description

The present randomized-controlled trial in kidney transplant patients aims to compare the outcomes and complications between who underwent immunosuppessive drug modification under surveillance-protocol biopsy and who underwent immunosuppressive drug modification following tough level only.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • All kidney transplant recipients underwent transplantation at Chulalongkorn University
Exclusion Criteria
  • Pregnancy
  • Recipients who cannot withhold aspirin, clopidogrel, warfarin, etc.
  • Non-cooperated recipients

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Protocol biopsySurveillance protocol kidney allograft biopsyPopulation in this arm will be adjusted immunosuppressive drug upon both pathological findings and the result of tough level.
Primary Outcome Measures
NameTimeMethod
Renal function24 months

24 h-CrCl

Secondary Outcome Measures
NameTimeMethod
Renal pathology24 months

interstitial fibrosis, rejection, calcineurin inhibitor toxicity

Complicationsimmediate, 1 month

hematoma, arteriovenous fistula

Trial Locations

Locations (1)

Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University

🇹🇭

Bangkok, Thailand

© Copyright 2025. All Rights Reserved by MedPath